Fibrinolytic therapy, also termed thrombolytic therapy, is a medical strategy designed to dissolve blood clots within the vascular system. The formation of blood clots, or thrombi, poses significant health threats by obstructing blood vessels and giving rise to conditions like pulmonary embolism or deep vein thrombosis. Utilizing fibrinolytic agents, such as tissue plasminogen activator (tPA), this intervention facilitates the breakdown of fibrin, a key protein in blood clot formation. The administration of fibrinolytic therapy is particularly time-critical, especially in acute scenarios such as pulmonary embolism, where prompt action can prevent or mitigate severe consequences. Despite its effectiveness, fibrinolytic therapy is not without risks, with potential complications including bleeding. Consequently, its application is judiciously weighed against individual patient factors and the specific clinical context. As medical research advances, ongoing exploration seeks to refine approaches, aiming to improve the safety and efficacy of fibrinolytic therapy, contributing to the continual enhancement of vascular care.
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, Tianjin University, China
Title : Not So Idiopathic After All: Genotype, Phenotype and IL-1 Blockade Response Converge in Recurrent Pericarditis
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Beyond the Heart in Cardiovascular Magnetic Resonance Imaging: Prevalence and Clinical Significance of Incidental Extracardiac Findings
burcu yagmur, Kyrenia University Hospital, Cyprus
Title : Cardiovascular mortality in colon cancer a patient characteristics analysis: Population-based study
Nouf, KAU, Saudi Arabia
Title : Improving Screening and Treatment of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction: A Two-Cycle Quality Improvement Project
Danish Malik, University Hospitals Dorset NHS Foundation Trust, United Kingdom